Gene mutation points to new way to fight diabetes, obesity, heart disease

Researchers say they have discovered a gene mutation that slows the metabolism of sugar in the gut, giving people who have the mutation a distinct advantage over those who do not. Those with the mutation have a lower risk of diabetes, obesity, heart failure, and even death. The researchers say their finding could provide the basis for drug therapies that could mimic the workings of this gene mutation, offering a potential benefit for the millions of people who suffer with diabetes, heart disease, and obesity.

The study, which is largely supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, appears in the Journal of the American College of Cardiology.

"We're excited about this study because it helps clarify the link between what we eat, what we absorb, and our risk for . Knowing this opens the door to improved therapies for cardiometabolic disease," said Scott D. Solomon, M.D., a professor of medicine at Harvard Medical School and a senior physician at Brigham and Women's Hospital in Boston, who led the research. He explained that the study is the first to fully evaluate the link between in the gene mainly responsible for absorbing in the gut—SGLT-1, or sodium glucose co-transporter-1—and cardiometabolic disease.

People who have the natural appear to have an advantage when it comes to diet, Solomon noted. Those who eat a high-carbohydrate diet and have this mutation will absorb less glucose than those without the mutation. A high-carbohydrate diet includes such foods as pasta, breads, cookies, and sugar-sweetened beverages.

In the study, the researchers analyzed the relationship between SGLT-1 mutations and cardiometabolic disease using genetic data obtained from 8,478 participants in the Atherosclerosis Risk In Communities (ARIC) study. The study was a 25-year-long observational trial of atherosclerosis and cardiovascular risk factors in people living in four U.S. communities.

The researchers found that about 6 percent of the subjects carried a mutation in SGLT-1 that causes limited impairment of glucose absorption. Individuals with this mutation had a lower incidence of type 2 diabetes, were less obese, had a lower incidence of failure, and had a lower mortality rate when compared to those without the mutation, even after adjusting for dietary intake (including total calories, sodium, and sugars).

Based on these findings, the scientists suggest that selectively blocking the SGLT-1 receptor could provide a way to slow down glucose uptake to prevent or treat cardiometabolic disease and its consequences. They caution that development of such targeted drugs could take years and that clinical trials are still needed to determine if the drugs reduce the incidence of diabetes and and improve lifespan.


Explore further

Disease causing mutation found in French-Canadians

More information: Sara B. Seidelmann et al, Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk, Journal of the American College of Cardiology (2018). DOI: 10.1016/j.jacc.2018.07.061
Provided by NIH/National Heart, Lung and Blood Institute
Citation: Gene mutation points to new way to fight diabetes, obesity, heart disease (2018, October 9) retrieved 19 January 2019 from https://medicalxpress.com/news/2018-10-gene-mutation-diabetes-obesity-heart.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more